SCHEMBL4175601

SCHEMBL4175601

O=C(Nc1cccc(C(F)C(F)F)c1)Nc1ccc2c(c1)COC2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.50
IMPDH2 P12268 2/20 0.49
PRMT3 O60678 1/20 0.49
NPC1 O15118 1/20 0.48
HSD17B10 Q99714 1/20 0.47
MTOR P42345 3/20 0.47
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PPIA P62937 1/20 0.44
NR3C1 P04150 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179300 0.79 KMT2A (0.59) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL13906680 0.76 MAPT (0.62) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL4175595 0.76 MAPT (0.56) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL4179509 0.76 MEN1 (0.65) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL4175593 0.75 PGR (0.53) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL29606212 0.74 MAPT (0.66) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL14144357 0.73 ROCK2 (0.61) MAPTKDM4EALDH1A1IMPDH2PRMT3
SCHEMBL5764438 0.73 MAPT (0.68) MAPTKDM4EALDH1A1IMPDH2NPC1
SCHEMBL20418656 0.72 NR3C1 (0.62) MAPTKDM4EALDH1A1IMPDH2NPC1
SCHEMBL23657911 0.72 PPIA (0.79) MAPTKDM4EALDH1A1IMPDH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082395-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082395-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, LTA4H MAPT 4061/4885KDM4E 1644/4885ALDH1A1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.